Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | DHODH | Q02127 | 1/20 | 0.60 |
| ▸ | MGAM | O43451 | 1/20 | 0.60 |
| ▸ | SI | P14410 | 1/20 | 0.60 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16742057 | 1.00 | GUSB (0.64) | GUSBGAAMEN1MAPTKMT2A | |
| SCHEMBL16742020 | 0.88 | GUSB (0.64) | GUSBGAAMEN1MAPTKMT2A | |
| SCHEMBL16742019 | 0.88 | GUSB (0.64) | GUSBGAAMEN1MAPTKMT2A | |
| SCHEMBL25613862 | 0.88 | GUSB (0.67) | GUSBGAAMEN1MAPTKMT2A | |
| SCHEMBL19631410 | 0.84 | DHODH (0.85) | GUSBGAAMEN1MAPTKMT2A | |
| SCHEMBL20956437 | 0.84 | DHODH (0.85) | GUSBGAAMEN1MAPTKMT2A | |
| SCHEMBL25614468 | 0.82 | DHODH (0.68) | GUSBGAAMEN1MAPTKMT2A | |
| SCHEMBL25613885 | 0.81 | GAA (0.72) | GUSBGAAMEN1MAPTKMT2A | |
| SCHEMBL14567100 | 0.80 | PTGS2 (0.63) | GUSBGAAMEN1MAPTKMT2A | |
| SCHEMBL1068115 | 0.80 | MAPT (0.74) | GAAMEN1MAPTKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| EP-3071199-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Genzyme Corporation (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015077535-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | GUSB 1002/4885GAA 167/4885MEN1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.